- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07907328
FUS Neuromodulation for Binge Eating Disorder
Early Feasibility Study of Focused Ultrasound (FUS) Neuromodulation in Patients With Binge Eating Disorder
This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of FUS neuromodulation in patients with Binge Eating Disorder (BED)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The primary objective is to evaluate the safety, feasibility and tolerability of FUS as an adjunct neuromodulatory treatment for BED
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Jennifer Marton
- Telefonnummer: 304-293-5886
- E-mail: jmarton@hsc.wvu.edu
Undersøgelse Kontakt Backup
- Navn: Padma Tirumalai
- Telefonnummer: 304-276-0500
- E-mail: ptirumalai@hsc.wvu.edu
Studiesteder
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
- West Virginia University: Rockefeller Neuroscience Institute
-
Kontakt:
- Study Coordinator
- Telefonnummer: 304-293-0930
- E-mail: tldeal@hsc.wvu.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
A candidate will be eligible if they meet all the following criteria:
- Age 18-80 years at time of enrollment.
- Diagnosis of moderate to extreme binge eating disorder (BED) per DSM-5-TR criteria
- Participant is able and willing to give informed consent.
- Participant is willing to cooperate with the study requirements, including compliance with the regimen, completion of all study visits, and study assessments.
- Participants of reproductive potential must have negative pregnancy test and agree to use acceptable forms of contraception.
- Participant able to communicate sensations during the procedure.
A candidate will be excluded if they meet any of the following criteria:
- Unable to undergo MR-imaging or clinically significant MRI findings
- History of any clinically significant neurological disorder.
- Evidence of substance (alcohol or other drug) use disorder during the previous 12 months .
- Past or present diagnosis of psychotic disorder or bipolar disorder
- Currently taking opioid pain medications or positive drug screen for opiates.
- If participants are on medication for the treatment of binge eating disorder or obesity (they must be on a stable dose for at least one month and agree to not begin a medication until after their Week 12 visit.
- Subject has a lifetime history or current symptoms consistent with bulimia nervosa or anorexia nervosa .
- Have a recorded or self-reported change in body weight >11 lbs. within 3 months prior to screening
- Have a prior or planned surgical treatment for obesity (excluding lap-band if removed >6 months prior to screening or liposuction or abdominoplasty if performed >1 year prior to screening)
- Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening
- History of medically verified suicide attempt within the past year. Clinically significant suicide risk
- Participant who is currently participating in another clinical investigation with an active treatment arm.
- Participant is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator.
- Participant is pregnant/ lactating or planning to be pregnant.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: FUS Neuromodulation
|
Subjects will undergo a single LIFU of the target brain region |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Occurrence of Treatment Emergent Adverse Events
Tidsramme: baseline compared to 4 and 12 weeks after study procedure
|
All adverse events that are related to FUS procedure will be assessed |
baseline compared to 4 and 12 weeks after study procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Food craving
Tidsramme: Week 4 and 12 comparisons will be made relative to baseline
|
Visual Analog scale |
Week 4 and 12 comparisons will be made relative to baseline
|
|
Change in Eating behavior
Tidsramme: Week 4 and 12 comparisons will be made relative to baseline
|
As measured by self-report binge eating, the Eating Disorder Examination-Interview (EDE-I), |
Week 4 and 12 comparisons will be made relative to baseline
|
|
change in eating Behavior
Tidsramme: Week 4 and 12 comparisons will be made relative to baseline
|
As measured by self-report binge eating Eating Disorder Examination Questionnaire EDE_Q |
Week 4 and 12 comparisons will be made relative to baseline
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Ali Rezai, WVU Rockefeller Neuroscience Institute
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- FUS_NMD_BED02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .